104720-70-9

Basic information

• Product Name: N-(3-nitrobenzyl)-2-phenylethanamine
• Synonyms: (3-Nitro-benzyl)-phenethyl-amine; benzeneethanamine, N-[(3-nitrophenyl)methyl]-
• CAS NO: 104720-70-9
• Molecular Formula: C₁₅H₁₆N₂O₂
• Molecular Weight: 256.2997
• Mol File: 104720-70-9.mol

Chemical Properties

• Boiling Point: 411.7°C at 760 mmHg
• Flash Point: 202.8°C
• Density: 1.164g/cm³
• Vapor Pressure: 5.47E-07mmHg at 25°C
• Refractive Index: 1.597
• CAS DataBase Reference: N-(3-nitrobenzyl)-2-phenylethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-nitrobenzyl)-2-phenylethanamine(104720-70-9)
• EPA Substance Registry System: N-(3-nitrobenzyl)-2-phenylethanamine(104720-70-9)

Safety Data

• Hazardous Substances Data: 104720-70-9(Hazardous Substances Data)

Upstream product

• 103-63-9 1-phenyl-2-bromoethane 

Downstream Products

• 1459261-15-4 tert-butyl (3-aminobenzyl)(2-phenylethyl)carbamate 
• 1459259-00-7 N-[3-[(2-phenylethylamino)methyl]phenyl]naphthalene-2-sulphonamide 

Relevant articles and documents

SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES

Sulphonamide derivatives of benzylamine of formula (I), wherein A represents phenyl unsubstituted or substituted; or 9- or 10-membered bicyclic group, linked to —(O)x—(CH2)y— through one of its aromatic carbon atoms, consisting of benzene ring fused with -membered heteroaromatic ring containing 1 or 2 heteroatoms independently selected from the group consisting of N and O, wherein such bicyclic group is unsubstituted or substituted or with 5- or 6-membered non-aromatic heterocyclic ring having 1 or 2 O atoms, wherein heterocyclic ring is unsubstituted or substituted with one or more C1-C3-alkyls; D represents a group selected from: phenyl unsubstituted or substituted; naphthyl unsubstituted or substituted; thiophene unsubstituted or substituted; bicyclic group consisting of imidazolering fused with 5-membered non-aromatic carbocyclic ring; bicyclic group consisting of benzene ring fused with 5-membered heteroaromatic ring, having 1 or 2 heteroatoms independently selected from the group consisting of N, O and S, unsubstituted or substituted and linked to sulphonamide moiety through one of carbon atoms of benzene ring; and bicyclic group consisting of benzene ring fused with—or 6-membered non-aromatic heterocyclic ring having 1 or 2 heteroatoms independently selected from the group consisting of N and O, unsubstituted or substituted, and linked to sulphonamide moiety through one of carbon N atoms of benzene ring; R represents H or —CH 3; x is 0 or 1; y is 2 or 3; and pharmaceutically acceptable salts and solvates thereof, with the provisos that if x is 0 and y is 2, then D is naphthyl unsubstituted or substituted with one halogen atom, and if R represents —CH 3, then A is not unsubstituted or substituted phenyl. The compounds can be used in the treatment and/or prophylaxis of central nervous system disorders.

SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES

Sulphonamide derivatives o f benzylamine of formula (I), wherein A represents phenyl unsubstituted or substituted;or 9-or 10-membered bicyclic group, linked to -(O)x - (CH2)y -through one of its aromatic carbon atoms, consisting of benzene ring fused with -membered heteroaromatic ring containing 1 or 2 heteroatoms independently selected from the group consisting of N and O, wherein such bicyclic group is unsubstituted or substituted or with 5-or 6-membered non-aromaticheterocyclic ring having 1 or 2 O atoms, wherein heterocyclic ring is unsubstituted or substituted with one or more C1-C3 - alkyls; D represents a group selected from:phenyl unsubstituted or substituted; naphthyl unsubstituted or substituted;thiophene unsubstituted or substituted;bicyclic group consisting of imidazolering fused with5-membered non-aromatic carbocyclic ring; bicyclic group consisting of benzene ring fused with 5-membered heteroaromatic ring, having 1 or 2heteroatoms independently selected from the group consisting of N, O and S, unsubstituted or substituted and linked to sulphonamide moiety through one of carbon atoms of benzene ring;and bicyclic group consisting of benzene ring fused with -or 6-membered non-aromatic heterocyclic ring having 1 or 2heteroatoms independently selected from the group consisting of N and O, unsubstituted or substituted, and linked to sulphonamide moiety through one of carbon atoms of benzene ring;R represents H or -CH3;x is 0 or 1 ;yis 2 or 3;and pharmaceutically acceptable salts and solvates thereof, with the provisos that if x is 0 and y is 2, then D is naphthyl unsubstituted or substituted with one halogen atom, and if R represents -CH3, then A is not unsubstituted or substituted phenyl. The compounds can be used in the treatment and/or prophylaxis of central nervous system disorders